Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on May 16, 2016. The filing discloses the entry into a material definitive agreement involving a First Amendment to a Loan and Security Agreement originally dated December 30, 2015, with lenders Oxford Finance LLC and East West Bank.
Key Financial Metrics and Transaction Details
- Debt Financing: The company secured the funding of the remaining $20.0 million under the Loan Agreement, structured as two $10.0 million tranches.
- Interest Rate: Interest on the Additional Loans accrues at a fixed annual rate of 9.25%.
- Repayment Terms: Payments are interest-only through July 1, 2017. Principal and interest payments commence August 1, 2017, with a maturity date of January 1, 2020.
- Final Payment Fee: The fee rate applicable to the Additional Loans was increased to 6.25%, resulting in an aggregate fee of $1.25 million upon repayment.
- Prepayment Penalty: A fee of 1.00% of the prepaid principal amount applies, in addition to the pro rata portion of the Final Payment Percentage.
- Equity Issuance: Omeros issued warrants to purchase an aggregate of 100,602 shares of common stock to the lenders.
- Warrant Terms: The warrants are exercisable for seven years at an exercise price of $9.94 per share.
Material Changes Versus Prior Period
The primary material change is the amendment of the original Loan Agreement to waive the net product revenue requirements previously necessary to draw down the remaining $20.0 million. Additionally, the cost of capital for these specific tranches increased, with the final payment fee rate rising from 5.25% to 6.25% to reflect the accelerated draw-down.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary regarding future revenue or product development. The transaction introduces specific financial obligations and dilution risks:
- Liquidity Impact: The company received $20.0 million in cash funding on May 18, 2016.
- Dilution Risk: The issuance of 100,602 warrants represents potential future dilution to existing shareholders.
- Covenant Waiver: The removal of revenue hurdles indicates the company may not have met the original performance metrics required for funding.
Investor Verification Checklist
- Verify the total outstanding debt balance following the $20.0 million draw-down.
- Confirm the current cash position and liquidity runway post-funding.
- Review the full text of the First Amendment (Exhibit 10.1) for any other modified covenants or default provisions.
- Assess the impact of the 100,602 warrants on fully diluted share count.
- Monitor the company's ability to meet the interest-only payments starting immediately and principal payments beginning August 2017.